APTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 gruod. 2023 @ 22:59):

Stats
Šios dienos apimtis	231 126
Vidutinė apimtis	132 918
Rinkos kapitalizacija	6.50M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0980
ATR14	$0.00400 (4.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-03	Khanna Ashish	Buy	375 000	Stock Option (Right to Buy)
2023-01-03	Riedel Norbert G	Buy	420 000	Stock Option (Right to Buy)
2023-01-03	Kidd Andrew	Buy	700 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 16 590 862 \| Sell: 1 518 818

Tūris Koreliacija

Ilgas: 0.42 (neutral)

Trumpas: 0.45 (neutral)

Signal:(66.425) Neutral

Aptinyx Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GNUS	0.981
UEIC	0.973
GMBL	0.966
QNRX	0.946
FAMI	0.945
BAND	0.945
JAGX	0.943
INFI	0.942
PIXY	0.94
GROM	0.938

10 Labiausiai neigiamai susiję koreliacijos
AGFS	-0.94
APEN	-0.935
LMRK	-0.889
SGEN	-0.885
KNBE	-0.884
TIG	-0.883
MYRG	-0.876
RDUS	-0.875
QADA	-0.871
IMRA	-0.862

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aptinyx Inc Koreliacija - Valiuta/Žaliavos

0.08
( neutral )

0.12
( neutral )

0.00
( neutral )

-0.48
( neutral )

0.00
( neutral )

Aptinyx Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.950

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.950

FY	2021
Pajamos:	$1.00M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0

FY	2020
Pajamos:	$1.56M
Bruto pelnas:	$1 564.00 (0.10 %)
EPS:	$-1.020

Financial Reports:

No articles found.

Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.